Gå videre til innhold

Pressemelding -

PRESS RELEASE: A new clinical trial shows that daily intake of Calanus® Oil improves body composition

A new study conducted by a research team from Leibniz Universität in Hannover, Germany, shows exciting synergistic effects on body composition when combining moderate physical activity with Calanus® Oil supplementation.

134 healthy, untrained participants (96 women and 38 men, average age 59 years, average BMI 28) took part in the 12-week interventional study. The participants were divided into four groups. All participants, except the control group, performed 2 hours of exercise per week. Additionally, one group was supplemented with Calanus® Oil and one group received dietary guidance.

“We see that intake of Calanus® Oil has a stronger impact on fat reduction and increase in lean body mass when compared to the other treatment groups, including the group receiving dietary guidance. These results are highly encouraging and show that Calanus® Oil impacts the energy metabolism of the body in a favorable direction beyond what can be explained by traditional omega-3 knowledge. This is the first human clinical trial to document body composition improvement, but we have already seen this in several preclinical studies”, says Head of Science in Calanus Alice Marie Pedersen, PhD.

The participants consuming Calanus® Oil, in addition to the exercise program, showed a reduction of 1,7 kg in fat mass and 0,8 kg increase in lean body mass, both significantly better than the other three study groups.

Pedersen explains that the marked improvement in body composition is probably multifaceted, and can be related to anabolic signaling in the muscle tissue and activation of specialized receptors in the distal intestine. These mechanisms are associated with improved insulin sensitivity.

“The totality of clinical findings shows that Calanus® Oil helps the metabolic tuning of the body by improving body composition, muscle function and insulin sensitivity. These benefits are very welcome in a time where obesity- induced disorders are a big threat to the public health”, concludes Head of Sales and Marketing Jan Erik Olsen, M.Sc.Pharmacy.

For further information please contact Head of Sales and Marketing Jan Erik Olsen on tel. +47 951 45 351 or by e-mail: jan.erik.olsen@calanus.no. Please also refer to the company's website: www.calanus.com.

Related links

Emner

Kategorier


Calanus As is a biomarine company pioneering harvesting and utilization of the crustacean Calanus finmarchicus, and is well positioned to play a key role in industrialization of the entire value chain through its intellectual property rights. Calanus As develops functional health- and nutrition ingredients for humans and animals exclusively from this valuable raw material. The Company’s main product is Calanus® Oil, an ecologically sustainable marine oil for humans. Calanus® Oil has unique composition and has shown benefits like improved insulin sensitivity, reduced deposition of intra-abdominal fat and powerful anti-inflammatory effects.

Kontakter

Snorre Angell

Snorre Angell

Pressekontakt CEO +4791349671

Relatert innhold

PRESS RELEASE: First Review Article on Health Effects of Wax Ester Omega-3s

A recent review article by Schots et al., published in Frontiers in Pharmacology, investigates how the different constituents of Calanus® Oil can contribute to the prevention of obesity-induced low-grade inflammation and the associated metabolic disturbances. Calanus® Oil is a natural oil derived from the 1-year copepod Calanus finmarchicus. In addition to having the unique wax ester form, Calanus

PRESS RELEASE: A new study shows that Calanus® Oil intake antagonizes negative changes in gut microbiota due to obesity

A new preclinical study conducted by a research team from Uit- The Arctic University of Norway, shows that Calanus® Oil supplementation in obese mice prevents negative changes in microbiota. This has led to new theories about the mechanisms of action of Calanus® Oil.
Current evidence suggests that obesity and its comorbidities are intrinsically linked with unfavorable changes in the intestinal

- Godt for deg. Godt for planeten.

Zooca® (Calanus AS) er et biomarint industriselskap som leder an i utvikling, fremstilling og salg av unike helse- og ernæringsprodukter basert på bærekraftig utnyttelse av det marine zooplanktonet raudåte (Calanus finmarchicus), en av de største fornybare marine ressursene globalt. Zooca® har gjennomført forskning og utviklingsarbeid innenfor høstingsteknologi, prosess- og applikasjonsutvikling, produktutvikling og dokumentasjon for kommersialisering. De primære forretningsområdene er ernærings- og helseprodukter til mennesker og dyr innenfor områdene kosttilskudd, funksjonelle ingredienser til oppdrett av marin fisk og reker, samt laksefisk og som ingredienser i pet food.

Hovedproduktene er Zooca® Calanus® Oil, som benyttes som høyverdig kosttilskudd hos mennesker, og Zooca® Hydrolysate, som benyttes funksjonell ingrediens i dyrefôr og startfôr innenfor oppdrett. Selskapet er den eneste bedriften i Norge som driver industriell utnyttelse av zooplankton.

Zooca (Calanus AS)

Stortorget 1, 5. etasje, Kystens hus
9008 TROMSØ
Norge